title: Cholangiocyte senescence by way of N-ras activation is a characteristic of primary sclerosing cholangitis.
abstract: Primary sclerosing cholangitis (PSC) is an incurable cholangiopathy of unknown etiopathogenesis. Here we tested the hypothesis that cholangiocyte senescence is a pathophysiologically important phenotype in PSC. We assessed markers of cellular senescence and senescence-associated secretory phenotype (SASP) in livers of patients with PSC, primary biliary cirrhosis, hepatitis C, and in normals by fluorescent in situ hybridization (FISH) and immunofluorescence microscopy (IFM). We tested whether endogenous and exogenous biliary constituents affect senescence and SASP in cultured human cholangiocytes. We determined in coculture whether senescent cholangiocytes induce senescence in bystander cholangiocytes. Finally, we explored signaling mechanisms involved in cholangiocyte senescence and SASP. In vivo, PSC cholangiocytes expressed significantly more senescence-associated p16(INK4a) and γH2A.x compared to the other three conditions; expression of profibroinflammatory SASP components (i.e., IL-6, IL-8, CCL2, PAI-1) was also highest in PSC cholangiocytes. In vitro, several biologically relevant endogenous (e.g., cholestane 3,5,6 oxysterol) and exogenous (e.g., lipopolysaccharide) molecules normally present in bile induced cholangiocyte senescence and SASP. Furthermore, experimentally induced senescent human cholangiocytes caused senescence in bystander cholangiocytes. N-Ras, a known inducer of senescence, was increased in PSC cholangiocytes and in experimentally induced senescent cultured cholangiocytes; inhibition of Ras abrogated experimentally induced senescence and SASP.
  
  
  CONCLUSIONS
  Cholangiocyte senescence induced by biliary constituents by way of N-Ras activation is an important pathogenic mechanism in PSC. Pharmacologic inhibition of N-Ras with a resultant reduction in cholangiocyte senescence and SASP is a new therapeutic approach for PSC.
authors.affiliation: Division of Gastroenterology and Hepatology, and the Mayo Clinic Center for Cell Signaling in Gastroenterology, Mayo Clinic, Rochester, MN.
authors.forename: James H
authors.initials: JH
authors.lastname: Tabibian
authors.forename: Steven P
authors.initials: SP
authors.lastname: O'Hara
authors.forename: Patrick L
authors.initials: PL
authors.lastname: Splinter
authors.forename: Christy E
authors.initials: CE
authors.lastname: Trussoni
authors.forename: Nicholas F
authors.initials: NF
authors.lastname: LaRusso
mesh_terms: D000328:Adult; D012634:Bodily Secretions; D016022:Case-Control Studies; D002478:Cells, Cultured; D016922:Cellular Senescence; D015209:Cholangitis, Sclerosing / Q000209:etiology / Q000378:metabolism / Q000503:physiopathology*; D004789:Enzyme Activation; D011905:Genes, ras; D006801:Humans; D008875:Middle Aged; D010641:Phenotype; D018631:ras Proteins / Q000037:antagonists & inhibitors / Q000378:metabolism*
chemical_list: D018631:ras Proteins